BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 17889446)

  • 21. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
    Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
    Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
    Finkle JH; Penney BC; Pu Y
    Lung Cancer; 2018 Sep; 123():136-141. PubMed ID: 30089584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist?
    Hanna GG; Carson KJ; Lynch T; McAleese J; Cosgrove VP; Eakin RL; Stewart DP; Zatari A; O'Sullivan JM; Hounsell AR
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1040-51. PubMed ID: 20350798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study.
    De Leyn P; Stroobants S; De Wever W; Lerut T; Coosemans W; Decker G; Nafteux P; Van Raemdonck D; Mortelmans L; Nackaerts K; Vansteenkiste J
    J Clin Oncol; 2006 Jul; 24(21):3333-9. PubMed ID: 16849747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
    Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
    Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer.
    Domachevsky L; Groshar D; Galili R; Saute M; Bernstine H
    Eur Radiol; 2015 Nov; 25(11):3361-7. PubMed ID: 25929940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
    J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
    Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.
    Reymen B; Van Loon J; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1319-24. PubMed ID: 23200174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated positron emission tomography and computed tomography in preoperative lymph node staging of non-small cell lung cancer.
    Xu N; Wang M; Zhu Z; Zhang Y; Jiao Y; Fang W
    Chin Med J (Engl); 2014; 127(4):607-13. PubMed ID: 24534208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy.
    van Diessen JN; Chen C; van den Heuvel MM; Belderbos JS; Sonke JJ
    Radiother Oncol; 2016 Mar; 118(3):447-52. PubMed ID: 26900092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Size of metastatic and nonmetastatic mediastinal lymph nodes in non-small cell lung cancer.
    Ikeda K; Nomori H; Mori T; Kobayashi H; Iwatani K; Yoshimoto K
    J Thorac Oncol; 2006 Nov; 1(9):949-52. PubMed ID: 17409977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Postoperative survival analysis of patients with stage Ⅲ-pN2 non-small cell lung cancer].
    Wu XW; Chen T; Yin S; Deng Y; Zhao B
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):782-786. PubMed ID: 30392344
    [No Abstract]   [Full Text] [Related]  

  • 38. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
    Nishiyama Y; Yamamoto Y; Kimura N; Ishikawa S; Sasakawa Y; Ohkawa M
    Ann Nucl Med; 2008 May; 22(4):245-50. PubMed ID: 18535874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
    Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
    Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Ohri N; Bodner WR; Halmos B; Cheng H; Perez-Soler R; Keller SM; Kalnicki S; Garg M
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):372-380. PubMed ID: 28068244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.